Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?

Recently, ATP synthase inhibitor Bedaquiline was approved for the treatment of multi-drug resistant tuberculosis emphasizing the importance of oxidative phosphorylation for the survival of mycobacteria. ATP synthesis is primarily dependent on the generation of proton motive force through the electron transport chain in mycobacteria. The mycobacterial electron transport chain utilizes two terminal oxidases for the reduction of oxygen, namely the bc1-aa3 supercomplex and the cytochrome bd oxidase. The bc1-aa3 supercomplex is an energy-efficient terminal oxidase that pumps out four vectoral protons, besides consuming four scalar protons during the transfer of electrons from menaquinone to molecular oxygen. In the past few years, several inhibitors of bc1-aa3 supercomplex have been developed, out of which, Q203 belonging to the class of imidazopyridine, has moved to clinical trials. Recently, the crystal structure of the mycobacterial cytochrome bc1-aa3 supercomplex was solved, providing details of the route of transfer of electrons from menaquinone to molecular oxygen. Besides providing insights into the molecular functioning, crystal structure is aiding in the targeted drug development. On the other hand, the second respiratory terminal oxidase of the mycobacterial respiratory chain, cytochrome bd oxidase, does not pump out the vectoral protons and is energetically less efficient. However, it can detoxify the reactive oxygen species and facilitate mycobacterial survival during a multitude of stresses. Quinolone derivatives (CK-2-63) and quinone derivative (Aurachin D) inhibit cytochrome bd oxidase. Notably, ablation of both the two terminal oxidases simultaneously through genetic methods or pharmacological inhibition leads to the rapid death of the mycobacterial cells. Thus, terminal oxidases have emerged as important drug targets. In this review, we have described the current understanding of the functioning of these two oxidases, their physiological relevance to mycobacteria, and their inhibitors. Besides these, we also describe the alternative terminal complexes that are used by mycobacteria to maintain energized membrane during hypoxia and anaerobic conditions.

Introduction

Mycobacterium tuberculosis (Mtb) causes tuberculosis (TB) and remains one of the leading causes of human deaths worldwide from a single infectious agent (W.H. Organisation, 2019). Management of TB relies on the WHO recommended chemotherapeutic regimen known as directly observed therapy short-course (DOTS) (W.H. Organisation, 2010). DOTS utilizes the administration of four antibiotics for 6 months. Such a lengthy treatment is associated with compliance issues, and is considered as one of the reasons for the emergence of drug resistance. The number of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB cases are steadily rising over the years (Seung et al., 2015). Given that the antimycobacterials used in DOTS were discovered several decades back, there is an urgent need for the development of newer drugs with distinct mechanisms of action. Fortunately, recently Bedaquiline (BDQ) (W.H. Organization, 2013), Pretomanid (Keam, 2019), and Delamanid (Ryan and Lo, 2014) were approved for the treatment of MDR-TB. Of these, Pretomanid and Delamanid belong to the class of nitroimidazole. Pretomanid targets cell wall biosynthesis as well as the respiratory electron transport chain (ETC) of Mtb and thus kills both replicating and non-replicating mycobacterial cells (Manjunatha et al., 2009). Delamanid primarily inhibits mycolic acid biosynthesis in Mtb (Thakare et al., 2015). BDQ belongs to the diarylquinoline class of drugs and inhibits ATP synthesis of Mtb (Andries et al., 2005). BDQ is capable of killing both actively replicating and non-replicating persistent mycobacterial cells (Rao et al., 2008). Mtb utilizes respiratory flexibility to survive under varying environmental conditions (Trivedi et al., 2012). Due to the presence of parallel and alternative components, ETC was considered a poor drug target (Iqbal et al., 2018). However, Pretomanid and BDQ both target Mtb bioenergetics and thus have established it as a validated target. Several reviews have earlier discussed the possibility of targeting oxidative phosphorylation to develop potential therapeutic antimycobacterials (Cook et al., 2014; Bald et al., 2017; Cook et al., 2017; Iqbal et al., 2018). Two reviews were recently published emphasizing the importance of respiratory terminal oxidases in mycobacterial physiology and their potential as drug targets (Lee et al., 2020; Mascolo and Bald, 2020). In line with these reviews, here we will discuss recent studies on the contribution of respiratory terminal oxidases to mycobacterial physiology, the recent development of inhibitors targeting them, and how these could be synergistically targeted for the development of a novel regimen for the treatment of TB. Besides, we will also describe the alternative electron acceptors utilized by mycobacteria for re-oxidizing the electron carrier menaquinone for maintaining an energized membrane.

Mycobacterial Electron Transport Chain

ETC is utilized by microorganisms for extracting reducing power from the reduced cofactors generated during catabolic processes. It utilizes membrane-anchored dehydrogenases that accept electrons from NADH/FADH2 and other reduced substrates and then transfer these electrons between a series of membrane-bound multi-protein complexes, finally transferring it to the enzymes catalyzing the reduction of oxygen to water, known as terminal oxidases (Magalon and Alberge, 2016). In this process of electron transfer, protons are pumped into the periplasm, generating a proton gradient that manifests a proton motive force (PMF) (Kashket, 1985; Cook et al., 2009). This force is utilized for ATP synthesis through ATP synthase (Walker, 2013). Mycobacterial cells utilize a large number of dehydrogenases for feeding electron into the ETC (Cook et al., 2014). However, NADH/menaquinone and succinate dehydrogenase (SDH) act as primary electron feeders in mycobacterial cells (Cook et al., 2014; Iqbal et al., 2018). Mtb contains a proton-pumping type I NADH dehydrogenase encoded by nuoABCDEFGHIJKLMN operon and two non-proton pumping type II NADH dehydrogenases encoded by ndh (Rv1854c) and ndhA (Rv0392c) (Cook et al., 2014; Iqbal et al., 2018). Most of the mycobacterial species contain two isoforms of SDH; SDH1 and SDH2 (Pecsi et al., 2014). In Mtb, the deletion of sdh1 disturbs the rate of respiration and leads to the inability to survive the long-term stationary phase. During aerobic growth, SDH1 functions as SDH, while SDH2 is dispensable for this catalysis (Hartman et al., 2014). SDH couples tricarboxylic acid cycle (TCA) with the ETC and feeds electron to the menaquinone pool. The pool of reduced menaquinones is then oxidized by two distinct terminal oxidases, namely menaquinol-cytochrome c oxidase (also known as cytochrome bc complex) and cytochrome bd-type menaquinol oxidase (bd oxidase) (Cook et al., 2014; Iqbal et al., 2018). These terminal oxidases transfer electrons from menaquinol to oxygen, and during this process, reduce oxygen to water. PMF generated through this cascade of electron transfer is utilized for the synthesis of ATP via ATP synthase ( ). Here it must be noted that, unlike Escherichia coli and many other bacterial species that can survive using substrate-level phosphorylation on fermentable carbon source, Mtb cannot grow using substrate-level phosphorylation and is dependent upon ATP synthase for ATP synthesis and growth on fermentable and non-fermentable carbon sources (Tran and Cook, 2005).

Figure 1

Schematic representation of the electron transport chain of mycobacteria. NADH dehydrogenase (Complex I) oxidizes NADH and transfers the electrons to cytochrome bc oxidoreductase (complex III-IV) by reducing menaquinone. Alternatively, succinate dehydrogenase (complex II) uses succinate as substrate and transfers electrons to complex III via menaquinone. Electrons are then transferred to cytochrome bc and cytochrome bd-type menaquinol oxidase (bd oxidase), which finally passes the electrons to the terminal electron acceptor, oxygen. During this process, a proton gradient is generated, which helps in the synthesis of ATP by ATP synthase. Inhibitors of the respiratory complexes are shown in red color.

Terminal Respiratory Oxidases

As mentioned above, mycobacterial cells use two terminal oxidases, namely, cytochrome bc supercomplex and cytochrome bd oxidase (Cook et al., 2014; Iqbal et al., 2018). Both of these contribute to the generation of PMF through the release of protons from menaquinol into periplasmic space. However, cytochrome bc complex is energetically more efficient as it pumps additional protons into the periplasm. In Gram-negative bacteria and the mitochondria of the eucaryotic cells, complex III (cytochrome bc) is linked to the complex IV (cytochrome aa) by a soluble cytochrome c. However, in Mycobacterium, complex III (cytochrome bc) is fused with the complex IV (cytochrome aa) to make a super complex (Megehee et al., 2006; Kim et al., 2015). This arrangement precludes the requirement of a soluble cytochrome c. A similar respiratory supercomplex is found in several genera under the phylum Actinobacteria (Kao et al., 2016), including Corynebacterium (Niebisch and Bott, 2003) and Rhodococcus (Sone et al., 2003). Although cytochrome bd oxidase is less energy efficient than the cytochrome bc complex, it is more versatile, has a higher affinity for oxygen (D’Mello et al., 1996), is induced under hypoxic stress (Parish et al., 2003), and also could help with the detoxification of hydrogen peroxide (Lindqvist et al., 2000) and antibacterials (Mascolo and Bald, 2020). Besides these main terminal oxidases, mycobacterial cells are equipped with alternative oxidases/hydrogenases that function during hypoxia or absence of oxygen. These oxidases/hydrogenases help mycobacteria in the sustenance of bioenergetics but are unable to support mycobacterial growth. Thus, these are believed to play an essential role in persistence and survival during stress conditions. In the following sections, we will try to make a case for the terminal oxidases as an important and synergistic drug target aimed at the development of novel antimycobacterials.

Cytochrome bc Complex and its Inhibitors

In the following section, we will describe the evolving understanding of the role of the cytochrome bc complex in mycobacterial physiology. We will also summarize the current knowledge of the inhibitors of the mycobacterial, the cytochrome bc complex.

bc Oxidoreductase Complex

In bacterial and mitochondrial respiratory chains, cytochrome bc (or complex III) extracts electrons from ubiquinone/menaquinone and then transfers them to membrane-anchored cytochrome c. Cytochrome bc pumps protons in the periplasmic space during electron transfer to cytochrome c (Berry et al., 2000). Cytochrome c then passes electrons to cytochrome c oxidase or cytochrome aa complex (also known as complex IV) that uses these electrons for reducing oxygen and couples the electron flow with proton translocation across the membranes (Capaldi, 1990). In mycobacteria, the complex III consists of a 2Fe/2S iron-sulfur cluster present on the Rieske protein (QcrA), a cytochrome b (QcrB) containing two b-type heme groups (low and high potential), and a di-heme c-type cytochrome c(QcrC) (Niebisch and Bott, 2001; Cook et al., 2017). The bc complex is a membrane-bound “hub” involved in the ETC of phylogenetically diverse species (Mulkidjanian, 2007). This complex is involved in the oxidation of menaquinol/ubiquinol. The Q-cycle mechanism has been proposed for explaining the functioning of the bc complex (Mitchell, 1976). According to the Q-cycle hypothesis, two electrons from ubiquinol/menaquinol are transferred to two different chains at the Qo-site of the complex. The first electron from quinol is transferred to the [2Fe-2S] cluster of the Rieske protein, that further transfers it to c type heme, and then later, the electron is passed on to complex IV. The second electron from quinol is passed to cytochrome b, harboring a low potential heme (bL) and a high potential heme (bH). These electrons are delivered to a second quinone on the Qi-site, and the quinone is reduced to quinol (Crofts et al., 2003). Complex IV (cytochrome aa) contains four redox active sites, namely CuA, CuB, heme a, and heme a (Scott, 1995). CuA (located on CtaC, subunit II) harvests electron from the cytochrome c and passes them to heme a (located on CtaS, subunit I), which then passes them to the dinuclear site composed of heme a and CuB (located on CtaD). The dinuclear site activates oxygen for reduction and rapidly passes four electrons converting it in water. During this process, besides consuming four scalar protons for protonation of oxygen, four vectoral protons are pumped out (Scott, 1995). The CtaS and CtaC are the primary electron acceptors from the bc1 complex, while the aCuB unit is the oxygen-reducing element (Cook et al., 2014).

In recent years, the concept of respirasomes has emerged (Krause et al., 2004). This concept suggests that different respiratory complexes associate with each other to make a supramolecular complex called “respirasome.” The organization and composition of such supercomplexes are believed to be dynamic and change with cellular energy requirements (Krause et al., 2004). In mitochondria, mostly complex I, complex III, and complex IV associate with each other in such supercomplexes (Krause et al., 2004; Lenaz and Genova, 2010; Dudkina et al., 2011). In line with these studies, a respiratory supercomplex consisting of complex III and complex IV has been reported for mycobacteria (Megehee et al., 2006; Kim et al., 2015). The mycobacterial cytochrome bc supercomplex contains tightly associated menaquinol reductase and an aa oxidase (Megehee et al., 2006; Kim et al., 2015; Gong et al., 2018). Importantly, cytochrome c is fused to the bc complex in Mycobacterium (Megehee et al., 2006). Another important difference of mycobacterial bc super complex from mitochondrial and eukaryotic III-IV supercomplex is that the former is tightly associated while the latter is only loosely associated. The atomic structure of cytochrome bc complex of M. smegmatis was recently elucidated using cryo-electron microscopy (Gong et al., 2018; Wiseman et al., 2018). These studies revealed detailed features of supercomplex, which are specific to mycobacteria. These studies suggested that around 20 subunits associate to form the respiratory supercomplex in mycobacteria. The core of the supercomplex is composed of a bc dimer that is sandwiched between aa complexes on each side (Gong et al., 2018; Wiseman et al., 2018). Interestingly, QcrA of mycobacteria possesses a roof-like structure towards the periplasm that facilitates the dimerization of the bc complex. This feature is unique to mycobacterial QcrA. The cyro-EM structure also revealed the role of previously unknown subunits, namely, Cta I, Cta J, LpqE, and prokaryotic respiratory supercomplex association factor 1 (PRSAF1) (Gong et al., 2018; Wiseman et al., 2018). LpqE and PRSAF1 are present at the interface of the bccomplex and aa complex. The structural analysis also revealed an association of superoxide dismutase (SOD) with the bc complex supercomplex ( ). These studies suggested that SOD may play a role in the detoxification of ROS formed by the bccomplex.

Figure 2

The cytochrome bcoxidoreductase supercomplex. (A) The passage of electron through various components of the cytochrome bcoxidoreductase. The crystal structure of cytochrome bc1-aa3 complex reveals its homo dimeric form. Each of the monomers is represented by a different color (orange and blue). The complex III is composed of a [2Fe-2S] cluster present on the Riske protein (QcrA), a cytochrome b (QcrB) containing two b-type heme groups (low and high potential), and a di-heme c-type cytochrome c(QcrC). Electrons are initially accepted by the QcrB subunit, which is transferred to the Fe-S complex in QcrA, releasing proton in the periplasmic space. Electrons are then passed to cytochrome c of the QcrC subunit via cytochrome c. CuA (located on CtaC, subunit II) harvests electrons from the cytochrome c and transfers them to heme a (located on CtaS, subunit I), which then passes them to the dinuclear site composed of heme a3 and CuB (located on CtaD). The dinuclear site activates oxygen for reduction and rapid transfer of four electrons converting it to water. (B) Schematic representation of cytochrome bcsubunits and their inhibitors. Cytochrome bcforms complex III and IV of the ETC of Mycobacterium species and has proved to be novel drug target against the bacteria.

Importantly, since the bc complex supercomplex is critical for the optimal growth of mycobacterial cells, the expression of its subunits is tightly controlled. Under conditions favoring aerobic respiration, the bc-aa supercomplex is the primary respiratory route in Mtb, yielding more ATP, and thus is essential for the mycobacterial growth (Matsoso et al., 2005; Cook et al., 2014). In response to the optimal oxygen levels, the expression of the two oxidases is regulated by mycobacteria to maximize the utilization of the terminal electron acceptor. It is assumed that the oxygen affinity of two-terminal oxidases is different (Cook et al., 2014), but whether the same is true is not analyzed. Notably, the presence of cytochrome bc supercomplex in M. smegmatis bd mutant enables it to grow at a similar rate to the wild type, suggesting that bc supercomplex alone can fulfill the energy needs of mycobacteria under normoxic conditions (Kana et al., 2001; Megehee and Lundrigan, 2007; Lu et al., 2015). These findings are in agreement with the observation that mutants of M. smegmatis and Mtb lacking QcrCAB are attenuated for growth (Kana et al., 2001; Matsoso et al., 2005; Beites et al., 2019). However, during the early phase of mice infection, the expression of the bc-aa complex is downregulated and stabilizes by around three weeks (Shi et al., 2005a). These observations are supported by the delayed growth of Mtb qcrCAB mutant in mice (Beites et al., 2019). Although a mutant of Mtb lacking a functional bc-aa complex can be generated, suggesting that this terminal oxidase in not essential in Mtb (Small et al., 2013; Beites et al., 2019), but several inhibitors of this complex can inhibit the Mtb growth in cultures, in macrophages, and during the infection emphasizing on its significance for mycobacterial growth.

bc Oxidoreductase Inhibitors

The role of the bc-aa supercomplex in optimal growth and its distinct structure and function from the mammalian respiratory system make it a relevant druggable target. Various well-characterized inhibitors of the mitochondrial, as well as mycobacterial bc complex, are known. Crystallographic studies and deducing their mechanism of action has led to the development of various other inhibitors for therapeutic purposes. Usually, these inhibitors target the catalytic domains of complex utilizing the structure analogous to quinone or quinol (Abrahams et al., 2012). A variety of chemical compounds and antibiotics are known to inhibit the bc complex for a long time. Myxothiazol from Myxococcus fulvus, a well-known antibiotic targeting the mitochondrial cytochrome b, was first characterized in 1984. It was shown to interact with both cytochrome b as well as the iron-sulfur protein of the complex resulting in the displacement of a quinone from the high-affinity binding site of the iron-sulfur protein (von Jagow et al., 1984). Antifungal antibiotics, like mucidin (from basidiomycetes Oudemansiella mucida) and strobilurin A (from Strobilurins tenacellus), also inhibit the complex by binding at the same site as that of myxothiazol (Von Jagow et al., 1986). However, another antibiotic, antimycin binds to a different location, inhibiting the oxidation of the cytochrome b subunit (Kucera et al., 1988). Stigmatellin, an antibiotic synthesized by Stigmatella aurentica, contains a 5,7-dimethoxy-8-hydroxychromone aromatic headgroup with a hydrophobic alkenyl chain in position 2. It directly binds to the cytochrome b Q0 site, associating with QcrA (von Jagow and Link, 1986).

To target a pathogen, it is important to identify compounds that are specific to the bacterial respiration pathway. This is achieved mainly by using high throughput screening (HTS), using which a plethora of cytochrome bc inhibitors have been discovered until now ( ). One such screening identified the imidazo[1,2-a]pyridine (IP) series of compounds. IPs were discovered as potent inhibitors of Mtb and M. bovis BCG. Four IP inhibitors were specifically targeting QcrB, forcing the bacterium to use energetically less efficient cytochrome bd oxidase. Among these compounds, 2,6-Dimethyl-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide with a minimum inhibitory concentration (MIC) of 0.03 µM was found to be the most potent molecule (Abrahams et al., 2012). In 2013, Pethe et al. reported a more active and less toxic class of imidazopyridine amides (IPA), targeting the Mtb cytochrome bc. The compound, Q203 (Telacebac), was found to be active against Mtb H37Rv at an MIC50 of 2.7 nM in vitro and MIC50 of 0.28 nM inside the macrophages (Pethe et al., 2013). However, it must be noted that Q203 is bacteriostatic only, as mycobacteria can utilize cytochrome bd oxidase for survival in presence of Q203 (Kalia et al., 2017a). In agreement with these observations, Q203 is bactericidal for Mtb strains lacking cytochrome bd oxidase (Kalia et al., 2017a). This compound was further optimized against MDR and XDR clinical isolates in the nanomolar range (Kang et al., 2014). This leading drug candidate has recently progressed to the clinical development phase II under U.S. FDA investigational new drug application. A screen for the spontaneous resistant mutants identified the cytochrome bc complex (qcrB) as the target of Q203. A mutation of Thr313 to either alanine or isoleucine was specifically involved in the resistance to Q203 (Pethe et al., 2013). In a cytochrome bd oxidase knockout mutant, Q203 completely inhibited the respiration (Lamprecht et al., 2016). Also, the chemical inhibition of cytochrome bd oxidase by aurachin D has been shown to turn the bacteriostatic activity of Q203 into bactericidal activity in Mtb and M. smegmatis (Lu et al., 2018). It is already evident that efflux pumps play a significant role in drug resistance in Mtb (da Silva et al., 2011). Verapamil (efflux pump inhibitor), in combination with Q203, increases the potency of the drug, showing the importance of efflux pumps mediated resistance and combination therapy with inhibitors to combat the problem (Jang et al., 2017). Putative 3D structures of the wild-type and T313A mutant along with the docking analysis with Q203 have been published, which can give insights for the resistance mechanism and will be beneficial for making better compounds within the IPA series (Ko and Choi, 2016). Apart from that, Q203 has also been evaluated against non-tuberculous mycobacteria (NTM) M. abscessus (Mabs), which is also quickly emerging as a health concern worldwide. It was shown that Q203 is ineffective against Mabs due to a genetic polymorphism in the target gene (QcrB). However, the complementation of Mabs ΔqcrCAB with chimeric Mabs qcrCAB (amino acids changed to Mtb qcrCAB) led to the susceptibility of Mabs towards this drug, suggesting the involvement of respiratory pathways in the intrinsic resistance mechanism towards drugs in Mabs (Abrahams et al., 2012). Recently, AWE402, another inhibitor belonging to the IPA class, was synthesized, which is structurally related to Q203 and shows good activity with MIC of 0.005 µM towards Mtb (Moraski et al., 2013; Ward et al., 2017). Later, a report of identification of an imidazo[1,2-a]pyridine-3-carboxamide bearing a variety of different linkers revealed 2,6-Dimethyl-N-[2-(phenylamino)ethyl]imidazo[1,2-a]pyridine-3-carboxamide as a potent anti-TB compound with MIC of 0.041 µM - 2.64 µM against both drug-sensitive as well as drug-resistant strains of Mtb (Lv et al., 2017). A compound belonging to this class, N-(4-(4-Chlorophenoxy)benzyl)-2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamide (ND-09759) was also identified as a potent anti-TB molecule with an MIC of ≤0.006 µM or 0.0024 µg/ml. Its in vivo bactericidal activity in a mice infection model, and good pharmacokinetic (PK) properties established it as a potent anti-TB drug (Cheng et al., 2014). Imidazo[1,2-a]pyridine-3-carboxamide has also been shown to be active against M. avium strains in vitro and in vivo in the mouse infection model, showing the importance of these compounds as drug molecule against NTM infections as well (Moraski et al., 2016a). Using a scaffold hopping strategy, a series of novel IPA derivatives bearing an N-(2-phenoxy)ethyl moiety were designed, synthesized, and checked for in vitro inhibitory activity against both drug-sensitive H37Rv and drug-resistant clinical isolates. Compound IMB-1402 (N-(2-(4-Bromophenoxy)ethyl)-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide) displayed acceptable safety and PK properties with an MIC of 0.025 µg/ml against H37Rv (Wu et al., 2016). Zolpidem (N,N-dimethyl-2-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)acetamide; Ambien) is one of the best known and approved drug for the treatment of insomnia. Its striking structural similarity with imidazo[1,2-a]pyridine-3-carboxamides led to the discovery of Zolpidem’s anti-TB activity (Moraski et al., 2015). The rational redesign of the structural moieties found in Zolpidem resulted in the series of potent anti-TB compounds and 7-methyl-N-(4-methylbenzyl)-2-(p-tolyl)imidazo[1,2-a]pyridine-3-carboxamide was found to be the potent one with MIC of 0.004 µM demonstrating the inherent in vitro potency, selectivity, and low toxicity of imidazo[1,2-a]pyridines (Moraski et al., 2015).

Table 1

Summary of cytochrome bc-aa supercomplex inhibitors, their chemical structures and MIC values. Number in the parentheses denotes the references.

Chemical Class	Name of the Compound	Chemical Structure	MIC
Imidazopyridine amides (IPAs)	2,6-Dimethyl-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide (Megehee and Lundrigan, 2007)		0.03 µM
	Telacebac (Q203) (Abrahams et al., 2012)		2.7 nMa
	AWE402 (Kang et al., 2014; Lamprecht et al., 2016)		0.005 µM
	2,6-Dimethyl-N-[2-(phenylamino)ethyl] imidazo [1,2-a]pyridine-3-carboxamide (Lu et al., 2018)		0.041 µM
	N-(4-(4-Chlorophenoxy)benzyl)-2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamide (ND-09759) (da Silva et al., 2011)		0.006 µM
	N-(2-(4-Bromophenoxy)ethyl)-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (IMB-1402) (Ko and Choi, 2016)		0.027 µg/ml
	Zolpidem (Ward et al., 2017)		10-50 µM
	7-Methyl-N-(4-methylbenzyl)-2-(p-tolyl)imidazo[1,2-a]pyridine-3-carboxamide (Ward et al., 2017)		0.004 µM
Imidazopyridine ethers (IPEs)	4-Fluoro-N-(3-((2-(4-fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)oxy)propyl)-3-methylaniline (Moraski et al., 2013)		0.03 µM
Pyrazolopyridine carboxamide (PPA)	TB47 (Lv et al., 2017)		0.016 µg/ml
Imidazo[2,1-b]thiazole-5- carboxamide	ND-11543 (Moraski et al., 2016a)		0.004 µM
Pyrrolo[3,4-c]pyridine- 1,3(2H)-dione	7-Amino-2-(3-chlorobenzyl)-4-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione (Wu et al., 2016)		0.065 µM
Quinazolinamine	2-(Ethylthio)-7,8-difluoro-N-methylquinazolin-4-amine(Compound 11726148) (Moraski et al., 2015)		0.05 µg/ml
Morpholinothiophene	5-Morpholino-3-phenethoxythiophene-2-carboxamide (Tantry et al., 2017)		0.024 µM
Thieno-pyrimidines	CWHM-1023 (Lu et al., 2019)		83 ± 5.4 nMa
2-(Quinolin-4-yloxy) Acetamide	GSK 358607A (Moraski et al., 2020)		1.11 µM
	2-((6-Methoxy-2-methylquinolin-4-yl)oxy)-N-(naphthalen-2-yl)acetamide(INCT-TB422) (Cleghorn et al., 2018)		0.05 µM
	2-((6-Methoxy-2-methylquinolin-4-yl)oxy)-N-(4-pentylphenyl)acetamide (Cleghorn et al., 2018)		0.005 µM
Arylvinylpiperazine amide	AX-35 (Ballell et al., 2013)		0.3 µM
Benzimidazole	N-(3-(2-Ethyl-6-methyl-1H-benzo[d]imidazol-1-yl)propyl)aniline(IDR-0578347) (Pitta et al., 2016)		0.056 µMb
	Lansoprazole (Pissinate et al., 2016; Borsoi et al., 2020)		1.13 µM
Quinolinone	MTC420 (Foo et al., 2018)		0.14 µMc
	SCR0911 (Ananthan et al., 2009)		272 µMa

aMIC50 value. bMIC99 value. cMIC50 (MDR Mtb).

Another robust screening of 900,000 compounds and their SAR analysis revealed imidazo[1,2-a]pyridine ethers as inhibitors of ATP synthesis and targeting cytochrome bcoxidase of Mtb. This screening resulted in the discovery of 4-Fluoro-N-(3-((2-(4-fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)oxy)propyl)-3-methylaniline as anti-TB agent having an MIC of 0.03 µM against Mtb (Tantry et al., 2017).

Similarly, due to the structural similarities with Q203, TB47, a pyrazolo[1,5-a]pyridine-3-carboxamide, was identified as a potent anti-TB drug molecule, showing MIC between 0.016 and 0.500 μg/ml against various clinical strains of sensitive, MDR as well as XDR strains of Mtb. It was shown to efficiently inhibit oxygen consumption in the cytochrome bd mutant strain of M. smegmatis. The target of this compound was found to be cd2-loop of qcrB (H190 in M. smegmatis). Metabolomics profiling suggested the accumulation of TCA cycle intermediates linked to reducing-equivalents upon TB47 treatment, suggesting the toxicity by the compound to be mediated by metabolic redox stress. Like other QcrB inhibitors, it shows a bacteriostatic effect. However, upon the deletion of cytochrome bd oxidase, it becomes bactericidal. Also, in mice model of Mtb infection, it shows promising synergy with pyrazinamide and rifampicin, proving it to be an effective lead compound for the development of novel anti-TB chemotherapy (Lu et al., 2019).

Later, another class of compound targeting QcrB, the imidazo[2,1-b]thiazole-5-carboxamides were identified as a promising new scaffold, showing potent anti-TB activity against Mtb in vitro, inside macrophages, and MDR-TB with very low cytotoxic activity (Moraski et al., 2016b). These compounds show MIC90 ranging from 0.0625 µM - 2.5 µM against Mtb, along with potency towards mono-drug resistance strains in a concentration ranging from 0.0017 µM - 7 µM. A recent study demonstrated its good in vitro ADME properties including, protein binding, CaCo-2, human microsomal stability, and CYP450 inhibition. They also demonstrated the good efficacy of a tool compound, ND-11543, in the murine TB infection model (Moraski et al., 2020).

Another HTS of the library of small polar molecules led to the identification of compounds showing activity against Mtb. Still, the presence of ester linkage imposed a question over their metabolic instability. So the compounds were optimized to get good metabolic stability in mouse PK studies yielding more stable Pyrrolo[3,4-c]pyridine-1,3(2H)-dione and showing MIC90 in the micromolar range against Mtb. Among those, 7-Amino-2-(3-chlorobenzyl)-4-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione had an MIC of 0.065 µM (van der Westhuyzen et al., 2015). These compounds are hyperactive against cytochrome bd oxidase mutants, and a point mutation (Ala317Thr) in qcrB results in resistance towards these compounds, strongly indicating the target to be the QcrB subunit (van der Westhuyzen et al., 2015).

Further, new potent quinazoline derivatives were synthesized and investigated for anti-TB activity. This study yielded a series of 2-ethylthio-4-methylaminoquinazoline derivatives against Mtb. They tested 76 derivatives, out of which four ((11626141, 11626142, 11626252, and 11726148) had good activity (MIC below 0.09 µg/ml). These compounds had very low cytotoxicity in human hepatocytes. Compounds 11626252 (2-(ethylthio)-8-fluoro-N-methylquinazolin-4-amine) and 11726148 (2-(ethylthio)-7,8-difluoro-N-methylquinazolin-4-amine) were also active in mice model of TB infection, showing 0.51 log10 CFU/organ upon treatment for 10 days. Surprisingly, the analysis of mutants showing resistance towards these compounds identified QcrA and QcrB as the target of these compounds. This was the first report which identified QcrA as an important druggable target. Compound 11626252 is bacteriostatic, but in a strain of Mtb lacking cytochrome bd oxidase (H37Rv ΔcydAB), it becomes bactericidal (Lupien et al., 2020). This proves that combination therapy of drug molecules targeting both the branches of Mtb aerobic respiration could be a new therapeutic regimen.

An aerobic whole-cell phenotypic screening of Eli Lilly corporate library against Mtb resulted in the identification of a cluster of a novel morpholino-thiophenes series. This screen resulted in the identification of tool compounds like 5-morpholino-3-phenethoxythiophene-2-carboxamide. These compounds had MIC90 in the micromolar range with no cytotoxicity and were active in an acute murine model of infection. Again, the target of these compounds was QcrB, proving it to be a crucial druggable target (Cleghorn et al., 2018).

In another study, a class of QcrB inhibitors was discovered, known as 4-amino-thieno[2,3-d]pyrimidines, that are chemically distinct from previously identified inhibitors, adding to the growing chemical space that can be exploited for the generation of new compounds with anti-TB activity. The most potent compound from their SAR analysis yielded CWHM-1023 having MIC50 of 83 ± 5.4 nM against Mtb. In combination with Q203, CWHM-1023 efficiently decreased the ATP levels in M. smegmatis and Mtb. Also, upon the deletion of cydA, bacteria become more sensitive towards this compound, proving its efficacy as an anti-TB drug molecule (Harrison et al., 2019).

In 2013, GlaxoSmithKline (GSK) made the results of an anti-mycobacterial phenotypic screening publically available. A total of 177 hits were reported, belonging to different structural classes (Ballell et al., 2013). Out of them, five 2-(quinolin-4-4-yloxy)acetamides (QOAs) exhibited potent anti-mycobacterial properties (MIC90 of 0.3 µM - 3.3 µM). Out of them, GSK 358607A was further investigated for its anti-TB activity using a preliminary SAR, leading to the identification of four analogs that were more potent than the original inhibitor. This class was also shown to target QcrB (Phummarin et al., 2016). The problem with these compounds was their moderate metabolic stability, due to the amide group lability (Pitta et al., 2016; Giacobbo et al., 2017). SAR studies of QOAs resulted in the discovery 2-((6-Methoxy-2-methylquinolin-4-yl)oxy)-N-(naphthalen-2-yl)acetamide (INCT-TB422), with an MIC of 0.05 μM and 2-((6-Methoxy-2-methylquinolin-4-yl)oxy)-N-(4-pentylphenyl)acetamide with an MIC of 0.005 μM against Mtb H37Rv (Pissinate et al., 2016). It was shown to be active against intracellular and drug-resistant Mtb strains as well (Giacobbo et al., 2017). Recently, another group conducted molecular simplification of these compounds yielding more stable and active even towards MDR-TB. The compounds thus generated were active in a macrophage model of TB infection (Borsoi et al., 2020).

Another study was focused on arylvinylpiperazine amides, which were also identified in the screen conducted by GSK. One of them was GW861072X (AX-35), which showed MIC90 of 0.3 µM against Mtb and M. bovis BCG. Lead optimization of this compound led to the identification of analogs with potent activity against Mtb in vitro and inside macrophages with mild cytotoxicity. These compounds were also active in an acute mouse model of TB infection, proving to be a good candidate against Mtb (Foo et al., 2018).

Further, HTS of a chemical diversity library containing 100,997 compounds was screened to identify a specific class of compounds showing anti-TB activity. It led to the discovery of the phenoxy-alkyl benzimidazole (PAB) class of compounds. They were showing a nanomolar range of MIC90 and very low cytotoxicity (Ananthan et al., 2009; Chandrasekera et al., 2015). Later, isolation of mutants resistant to PAB compounds showed mutations either in rv1339, a gene of unknown function, or qcrB (Chandrasekera et al., 2017). SAR studies of PABS yielded improved compounds with alkylbenzimidazole moiety. Several compounds were even active against intracellular bacteria, out of which the compound N-(3-(2-ethyl-6-methyl-1H-benzo[d]imidazol-1-yl)propyl)aniline (IDR-0578347) was most potent with MIC99 of 0.056 ± 0.020 µM (Chandrasekera et al., 2017). Already known gastric proton pump inhibitor, lansoprazole (LPZ, Prevacid), which is extensively used to treat acid-related stomach disorders, was found to possess intracellular activity against Mtb. Target identification studies revealed its target to be cytochrome bccomplex by intracellular sulfoxide reduction to lansoprazole sulfide. A single nucleotide polymorphism of leucine-176 to proline in the cytochrome b results in the resistance towards this drug. LPZ rapidly converted to lansoprazole sulfide (LPZS), a potent anti-mycobacterial agent, cannot bind to human H+K+ -ATPase and thus can be used as a drug molecule (Rybniker et al., 2015). But in vivo, LPZ does not yield a sufficient amount of LPZS to be active against Mtb, while a single intravenous dose of pure LPZS does results in higher tissue concentration, adequate to kill Mtb (Mdanda et al., 2017). LPSZ is highly specific and possesses potent activity against drug-resistant isolates of Mtb (Rybniker et al., 2015). Through modeling of mutant mycobacterial protein on the published QcrB protein, it was revealed that both L176P (mutation leading to resistance towards LPZS) and T313A (resistance towards IPA) were localized to the same site, i.e., ubiquinol oxidation (P site). But, L176P mutants remained susceptible to various IPA, and T313A mutants were susceptible to LPZS, revealing a different binding mechanism for them (Rybniker et al., 2015).

A compound of quinolinone class, MTC420, synthesized by Hong and coworkers, has been reported as the cytochrome bc inhibitor with an MIC value of 0.14 μM (Hong et al., 2017). Another repurposing strategy led to the identification of an anti-malarial compound as an anti-TB agent, inhibiting cytochrome bc oxidase, SCR0911. It showed an MIC50 of 272 ± 41 μM against M. smegmatis and 107 ± 5.8 μM against M. bovis BCG. Also, SCR0911 resulted in rapid intracellular ATP depletion in mycobacteria, indicating the interruption of electron flow. Docking studies revealed the Qi site of mycobacterial cytochrome bcto be the potential target of this drug. This opens the door for the SAR analysis of this compound for improved and specific drug molecules against Mtb (Chong et al., 2020).

Despite the high vulnerability of this respiratory branch, it is surprising to note that the screening of compounds targeting the supercomplex has majorly identified the compounds inhibiting the narrow region of QcrB subunit (Arora et al., 2014; Rybniker et al., 2015) ( ). A recent optimal homology model of Mtb QcrB using M. smegmatis QcrB as a template was built. This could provide a more in-depth insight into the interaction of Mtb QcrB with its inhibitors (Pan et al., 2019). However, exciting drug-development has been done in recent times, the absence of bcsupercomplex results in the upregulation of cytochrome bd oxidase to meet the energetics demand of Mycobacteria (Matsoso et al., 2005; Arora et al., 2014), which demands a much better understanding of the mycobacterial ETC to target the mycobacterial cytochrome bc oxidoreductase supercomplex. Although the same is not valid in the case of the clinical isolate, which regulates cytochrome bd expression more tightly (Rybniker et al., 2015).

Cytochrome bd Oxidase and its Inhibitors

In the following section, we will describe the current understanding of the role of cytochrome bd oxidase in mycobacterial physiology. We will also describe currently known inhibitors of the mycobacterial cytochrome bd oxidase.

Cytochrome bd Oxidase

Cytochrome bd oxidase is confined to the prokaryotic world and thus is considered a plausible drug target. Unlike cytochrome c oxidase, it does not pump protons to the periplasm and therefore is not energy efficient (Borisov et al., 2011). However, it still helps in the generation of PMF through the vectorial charge transfer of protons (Borisov et al., 2011). It has been purified and characterized from E. coli (Miller and Gennis, 1983), Azotobacter vinelandii (Junemann and Wrigglesworth, 1995), Corynebacterium glutamicum (Kusumoto et al., 2000), and Geobacillus thermodenitrificans (previously Bacillus Stearothermophilus) (Sakamoto et al., 1996). The long-awaited crystal structure of cytochrome bd oxidases was recently solved for enzymes from Geobacillus thermodenitrificans and E. coli (Safarian et al., 2016; Safarian et al., 2019; Theßeling et al., 2019). Mycobacterial cytochrome bd oxidase is not extensively studied and is assumed to share similar functions to the closest structural bacterial homologs. Analysis of the Mtb genome suggests that Mtb cytochrome bd oxidase comprises of two main canonical subunits, namely CydA and CydB. In the Mtb genome, genes encoding for CydA, CydB, CydC, and CydD are present in an operon. The function of CydC and CydD is not clear, but they are assumed to be cytochrome ABC type cysteine exporter, which may facilitate the proper assembly of the cytochrome bd oxidase (Cruz-Ramos et al., 2004). In M. smegmatis, the cydDC and cydAB are located on separate operons parted by 100 base pairs (Aung et al., 2014). Sequence comparison of CydA and CydB across several mycobacteria reveal higher similarity in the sequence of cydA compared to cydB. This observation is in concordance with the norm of asymmetrical evolution of cytochrome bd subunits (Hao and Golding, 2006). It has been demonstrated that sensitivity to respiratory inhibitors such as hydrogen cyanide and pyocyanin significantly varies by microevolution of cydB (Voggu et al., 2006); however, in mycobacteria, it has not been explored yet. The sequences of cydA and cydB in Mtb is 100% identical to M. bovis BCG, making BCG a useful model organism to study cytochrome bd oxidase. Subunit CydA is involved in the oxidation of the menaquinol. It contains a q loop that binds to menaquinol and three heme groups that act as redox centers for transferring the electron flux across the terminal oxidase. These three heme are low spin cytochrome b, high spin-b and chlorin type heme d. Recently, the homology model of cytochrome bd oxidase has been created (Sviriaeva et al., 2020) by utilizing the crystal structures of the enzymes from G. thermodenitrificans and E. coli (Safarian et al., 2016; Safarian et al., 2019). Comparing the mycobacterial and bacterial amino acid sequence shows that the menaquinol binding Q loop region in mycobacterial cytochrome bd oxidase harbors various residues that are unique and different from bacterial orthologs (Sviriaeva et al., 2020). Given the uniqueness of the additional amino acid stretches in CydAB and the role of these in the function of cytochrome bd oxidase, these could be utilized in discovering mycobacteria specific inhibitors. In mycobacterial cytochrome bd oxidase, the presence of methionine residues around the catalytic site may be the reason for reactive oxygen species (ROS) scavenging and guarding the enzyme (Harikishore et al., 2020).

A variable regulation of cytochrome bd expression is seen across different mycobacterial species as the cydABDC genes can form a polycistronic operon in various bacteria (Kabus et al., 2007). E. coli cytochrome bd possesses a higher affinity for oxygen (D’Mello et al., 1996) and is induced under hypoxic conditions (Poole and Cook, 2000). Although the oxygen affinity of the mycobacterial CydAB has not been determined yet, it is known to be induced in response to hypoxia (Kana et al., 2001; Berney and Cook, 2010). Expression of cydAB is regulated by ubiquinone/ubiquinol sensor ArcA/ArcB in E. coli (Malpica et al., 2004), while in mycobacteria, it is regulated by the oxygen sensing two-component system SenX3/RegX3 (Roberts et al., 2011; Singh and Kumar, 2015) ( ). Additionally, cyclic AMP receptor protein regulates the expression of cydAB in M. smegmatis under hypoxic conditions (Aung et al., 2014). However, whether the same is true for the Mtb homolog of cyclic AMP receptor protein needs to be further explored. In line with these observations, the cydAB operon is induced in response to nitric oxide (Shi et al., 2005a) that inhibits mycobacterial respiration. Notably, the cydAB operon is also induced during chronic infection in mice lungs (Shi et al., 2005a), suggesting a role in mycobacterial survival in the mice lungs. Furthermore, Mtb cydAB mutants are attenuated for survival in mice during chronic infection (Shi et al., 2005a). These observations are in agreement with earlier observations wherein CydAB was shown to play an important role in virulence and survival of various bacterial pathogens inside the host (Juty et al., 1997; Zhang-Barber et al., 1997; Endley et al., 2001; Turner et al., 2003; Baughn and Malamy, 2004; Shi et al., 2005a; Yamamoto et al., 2005; Larsen et al., 2006). Although the precise role of CydAB in protection from the host system remains undefined, these observations suggest a role beyond maintaining cellular bioenergetics. Emerging evidence indicates that CydAB could play a role in imparting resistance towards oxidative and nitrosative stress (Junemann and Wrigglesworth, 1995; Hori et al., 1996; Winstedt et al., 1998; Lindqvist et al., 2000; Borisov et al., 2011), as well as to the low iron concentrations (Cook et al., 1998). These effects could be explained due to the capability of CydAB oxidase to detoxify ROS. E. coli CydAB is known to possess quinol peroxidase activity that leads to detoxification of hydrogen peroxide (Al-Attar et al., 2016). It is plausible that Mtb CydAB oxidase could also protect the bacilli from oxidative stress, but it remains to be analyzed. In agreement with this hypothesis, the cytochrome bd oxidase expression rises three-fold in Mtb strain lacking a functional cytochrome bc supercomplex, leading to increased resistance against H2O2 (Small et al., 2013). In classical strains of M. ulcerans and M. leprae, a functional cytochrome bd oxidase is absent, whereas, in Mtb, the enzyme may considerably protect the bacteria from multiple environmental stresses, including low oxygen tensions and nitric oxide or peroxides during infection in the human host (Cole et al., 2001; Berney et al., 2014; Scherr et al., 2018). In E. coli, cytochrome bd oxidase is overexpressed in biofilms. Loss of this enzyme results in the impairment of biofilm formation (Beebout et al., 2019). The role of cytochrome bd oxidase in mycobacterial biofilm formation still remains to be established.

Figure 3

Genetic regulation of cytochrome bd complex. The expression of cydB component of terminal oxidase cytochrome bd depends upon SenX3 – RegX3 two-component system specific to Mycobacterium. During the aerobic condition, phosphorylated RegX3 binds to the promoter region of cydB and inhibits transcription. However, during hypoxia, RegX3 gets dephosphorylated and does not bind to the promoter of cydB, thus facilitating its expression.

Cytochrome bd Oxidase Inhibitors

Cytochrome bd oxidase is specifically present in bacteria and thus could be used as a target for anti-TB drug development ( ). Furthermore, mycobacterial CydAB oxidase contains an extended menaquinone binding loop, and several additional stretches of amino acids essential for its function, making it amenable to Mtb specific drug targeting ( ). But the non-essentiality of cytochrome bd oxidase represents a challenge to identify its inhibitors. Not many compounds are known to inhibit cytochrome bd oxidase ( ). The Aurachin class of compounds is a quinone analog, which has been reported to inhibit a variety of cytochrome oxidases (Meunier et al., 1995; Debnath et al., 2012; Li et al., 2013). Aurachin D is well known among this class of compounds known to inhibit E. coli cytochrome bd oxidase (Meunier et al., 1995). It inhibits oxygen consumption in M. smegmatis in a dose-dependent manner. Optimized, derivatives of Aurachin D, with better ability to penetrate the mycobacterial cell wall, can become a new class of antitubercular drugs (Lu et al., 2015). Gramicidin S represents another class of compounds capable of inhibiting bd oxidase (Mogi et al., 2008). It is a cationic cyclic decapeptide and possesses potent antibiotic activity. Earlier models suggest that it perturbs the bacterial membrane to exert its antibiotic activity, but recent literature shows that it could also target bd oxidase (Mogi et al., 2008). Besides, Gramicidin S, another antimicrobial peptide Microcin J25 was shown to inhibit E. coli bd oxidase (Galvan et al., 2019). However, it remains to be seen if these antimicrobial peptides could inhibit the respiration of mycobacterial cells. Another study identified the prenylphenols class of compounds from the Kitasato Institute for Life Sciences Chemical Library to inhibit bd oxidases. Interestingly, prenylphenols LL-Z1272 beta and epsilon were specifically active against the bd oxidase (Mogi et al., 2009). Importantly, the utilization of the computational biology approach led to the identification of MQL-H2, a novel inhibitor of bd oxidase (Harikishore et al., 2020). This inhibitor is postulated to bind the menaquinol binding site of CydA and inhibits ATP synthesis in inverted membrane vesicles of M. smegmatis (Harikishore et al., 2020). In an interesting development, a quinolone derivative CK-2-63, and its analogs were identified as potent inhibitors of mycobacterial bd oxidase inhibitors (Ward et al., 2017). CK-2-63 alone partially inhibits the growth of Mtb in vitro cultures. Interestingly, this inhibitor, in combination with cytochrome bcc inhibitors and/or ATP synthase inhibitor Q203 was capable of killing mycobacterial cells (Ward et al., 2017).

Figure 4

Mycobacterial cytochrome bd oxidase. The components and inhibitors of terminal oxidase cytochrome bd and the passage of electron through its various subcomponents. The electron is finally accepted by oxygen, which accepts proton from the periplasm to form water.

Figure 5

Schematic representation of the effect of inhibition of both the terminal oxidases of Mycobacterium species. Inhibition of both the terminal oxidases leads to cell death. A combination of various drugs could directly target both of these terminal oxidases, which are specific to Mycobacterium and could effectively kill the bacteria, thus providing a novel drug target against Mycobacterium species.

Table 2

Summary of cytochrome bd oxidase inhibitors, their chemical structures and MIC values. Number in the parentheses denotes the references.

Compound name	Chemical structure	MIC value
Aurachin D (Lenaz and Genova, 2010)		>85 µM
MLQ-H2 (Berney et al., 2014)		34 µM
CK-2-63 (Kang et al., 2014)		0.003 µM

Alternative Respiratory Complexes

Respiratory complexes bc-aa supercomplex and cytochrome bd oxidase utilize oxygen as a terminal electron acceptor. However, during severe hypoxia and anoxia, oxygen is not readily available to act as an electron acceptor. Under such conditions, E. coli cells utilize alternative electron acceptors such as nitrate and fumarate for oxidizing the reduced pool of the electron carrier menaquinone. Importantly, under oxygen limiting conditions and upon inhibition of respiration, NADH levels are tremendously reduced along with lower levels of ATP (Watanabe et al., 2011; Bhat et al., 2016). Reoxidation of NADH is critical for mycobacterial cells to deter reductive stress and survive during such conditions (Mavi et al., 2020). Mycobacterium alters its ETC and central metabolic pathways to endure low levels of oxygen. In this section, we will describe the role of nitrate reductase (NR) and fumarate reductase (FRD) as a component of an alternative respiratory chain utilized by mycobacteria for survival during hypoxia and anoxia. It must be noted that these modulations only help mycobacteria to survive but do not facilitate mycobacterial growth.

Nitrate Reductase

NRs are families of enzymes that catalyze the reduction of nitrate into nitrite . The presence of this family of enzymes in bacteria was revealed way back in 1925 through the demonstration of nitrate aided anoxic bacterial growth (Quastel et al., 1925; Stewart, 1988). These enzymes are utilized for a multitude of functions ranging from respiration to assimilation and dissimilation of nitrate. A common defining characteristic of these enzymes is the utilization of the molybdenum cofactor for the reduction of nitrate (Morozkina and Zvyagilskaya, 2007). The catalytic molybdenum site is coordinated through bis-molybdopterin guanine dinucleotide (Diaes et al., 1999). Three types of NRs are found in bacteria, i.e., cytoplasmic assimilatory, membrane-bound respiratory, and periplasmic dissimilatory (Morozkina and Zvyagilskaya, 2007). Both the periplasmic dissimilatory and membrane-bound respiratory forms are known to assist growth during anaerobic conditions and are present in E. coli (Stewart et al., 2002; Morozkina and Zvyagilskaya, 2007). For this review, we will primarily focus on the membrane-anchored respiratory NR as it is the only functional NR in mycobacteria ( ). Respiratory NR is composed of three subunits (Stewart, 1988; Morozkina and Zvyagilskaya, 2007). Subunit γ is encoded by gene narI and it anchors the enzymatic complex to the membrane and captures electrons from reduced menaquinone using heme cofactors. Electrons are then passed onto the subunit β encoded by narH. NarH contains [Fe-S] clusters that facilitate the transfer of electrons to subunit α encoded by narG. Subunit α utilizes [Fe-S] and molybdenum cofactor to reduce nitrate into nitrite in the cytoplasm (Stewart, 1988; Morozkina and Zvyagilskaya, 2007). The expression of narGHIJ operon encoding the enzyme complex is tightly regulated by transcription factors like FNR, NarL, and NarP during anaerobic conditions or in the presence of nitrate (Stewart, 1994).

Figure 6

Nitrate reductase pathway in M. tuberculosis. Figure shows dependence of nitrate reductase pathway upon DosS-DosR two component system of Mtb. In stress conditions such as hypoxia, DosR upregulates expression of NarK2, which in turn, transports nitrate into the cytoplasm. This nitrate is reduced to nitrite with the help of NarGHI. In this process, electron from menaquinol are used for reduction of nitrate. Nitrate produced in the process is transported out, however the nitrate transporter remains to be identified.

Mtb possesses the capability to reduce nitrate into nitrite while other related mycobacterial species lack this ability. Significantly, this ability is historically utilized for the discrimination of Mtb from M. bovis (Virtanen, 1960; Escoto and de Kantor, 1978). Mtb has two genetic clusters bearing homology to genes encoding dissimilatory NRs, namely narGHJI operon and the narX gene of the narK2X operon (Sohaskey and Wayne, 2003). The narGHJI operon encodes for the classical respiratory NR. Overexpression of this operon manifests NR activity in M. smegmatis (Weber et al., 2000), and can complement the nar mutant of E. coli for NR activity (Sohaskey and Wayne, 2003). On the other hand, NarX is a fused NR that seems to lack functional NR activity since the deletion of this gene does not affect the NR activity of Mtb (Sohaskey and Wayne, 2003). In comparison, the disruption of NarG leads to the attenuation of NR activity in Mtb. Interestingly, the aerobic cultures of Mtb possess basal levels of NR activity, which is enhanced during adaptation to hypoxia (Wayne and Hayes, 1998). However, unlike the E. coli narGHJI operon, that is induced upon hypoxia and in the presence of nitrate through transcriptional regulators FNR and NarL, the expression of narGHJI operon of Mtb is not induced in response to hypoxia or nitrate (Sohaskey and Wayne, 2003). On the contrary, the increase in NR activity of Mtb in response hypoxia is associated with increased expression of nitrate transporter NarK2X (Sohaskey and Wayne, 2003). Mtb possesses three isomers of nitrate transporter NarK2X, namely NarK1, NarK3, and NarU. Out of these, NarK2X is part of the dos/dormancy regulon regulated by the DosRST two-component system that responds to hypoxia, carbon monoxide and nitric oxide (Park et al., 2003; Voskuil et al., 2003; Kumar et al., 2007; Kumar et al., 2008; Trivedi et al., 2012). In line with this, the expression of narK2 is induced during infection in mice (Shi et al., 2005b), suggesting that NR could aid in the survival of Mtb during hypoxia. However, the narG mutant is not attenuated for survival in hypoxia in the presence or absence of nitrate in the media (Sohaskey and Wayne, 2003). Furthermore, the expression of the narK2 and NarX are downregulated upon biofilm formation (Trivedi et al., 2016). These observations raise doubts on the role of the narGHJI operon (and NRs) in mycobacterial survival and respiration under anaerobic conditions. However, NR protects the hypoxic Mtb cells from the stress of reactive nitrogen species and acidic pH (Tan et al., 2010).

Mtb is known for its capability to shift down its metabolic state and acquire the state of non-replicating persistence in response to a gradual decrease in the oxygen levels (Kumar et al., 2011; Bhat et al., 2012). However, Mtb does not survive sudden anaerobiosis; the presence of nitrate in culture medium aids in the survival of Mtb during sudden anaerobiosis. Furthermore, NarG plays an essential role in this survival against the sudden removal of oxygen (Sohaskey, 2008). In agreement with these observations, mycobacterial survival in the presence of respiratory inhibitor Thioridazine is enhanced by nitrate and a functional NR (Sohaskey, 2008). Inhibition of respiration leads to the accumulation of NADH (Bhat et al., 2016). Accumulated NADH ultimately leads to oxidative stress (Mavi et al., 2020), and thus it is prudent for mycobacterial cells to modulate its respiration and metabolism to re-oxidize NADH.

An interesting property of NR of Mtb is that it is not oxygen sensitive, unlike other bacterial NRs (Pichinoty and D’Ornano, 1961). Mtb utilizes this property of NR and leads to NarG dependent accumulation of nitrite in Mtb infected human macrophages (Cunningham-Bussel et al., 2013). Nitrite affects the metabolism and growth of Mtb (Cunningham-Bussel et al., 2013). It was suggested that NR aid in the maintenance of redox homeostasis in Mtb (Sohaskey, 2008). Importantly, transcripts of NarG were detected in the pericavity and the distant lung regions in clinical lung samples (Rachman et al., 2006). Furthermore, the evidence for the importance of nitrate respiration in TB pathogenesis comes from the vaccine strain M. bovis BCG. Although BCG exhibit the low activity of NR, however, this activity is important for survival and tissue-specific persistence of BCG in immunocompetent and immunocompromised mice (Fritz et al., 2002). Despite the importance of NR in TB pathogenesis, it has not been used as a target for drug development. Although, a few compounds like Pentachlorophenol are known to inhibit the NR. These are used primarily as a pesticide and a disinfectant. However, the establishment of NR as a valid drug target and development of Mtb specific inhibitors need further research.

Fumarate Reductase and Bidirectional Succinate Dehydrogenases

Fumarate reductases (FRD) are the enzymes that catalyze the reduction of fumarate into succinate (Van Hellemond and Tielens, 1994). These enzymes are critical for organisms utilizing fumarate as the terminal electron acceptor. These enzymes are very similar to succinate dehydrogenases that catalyze the reverse reaction and convert succinate into fumarate while donating electrons to ubiquinone/menaquinone. Mtb genome encodes for a fumarate dehydrogenase (FRD, encoded by frdA-rv1556 operon) and two succinate dehydrogenases (SDH1, encoded by rv0247c–rv0249c and SDH2, encoded by rv3316–rv3319) (Cook et al., 2014; Iqbal et al., 2018). FRD can be found as a soluble enzyme, but the one that participates in the respiration is often membrane-anchored (Van Hellemond and Tielens, 1994). It is a polypeptide complex consisting of three to four subunits named; A, B, C, and D. Catalytic core is constituted by FRD-A and FRD-B, whereas other domain/s act as membrane anchor and harvest electrons from menaquinone/ubiquinone (Van Hellemond and Tielens, 1994). Importantly, the FRD of Mtb is induced upon exposure to hypoxia (Watanabe et al., 2011). Furthermore, hypoxic Mtb cultures accumulate succinate in media (Watanabe et al., 2011; Eoh and Rhee, 2013). Notably, during hypoxia, Mtb could utilize a reductive half TCA cycle to oxidize NADH (Eoh and Rhee, 2013). These observations suggest that FRD will be critical for the survival of Mtb during hypoxia and in animal models. However, the frdA deletion mutant is not attenuated for survival during hypoxia or inside animals (Watanabe et al., 2011). Furthermore, cultures of frdA deletion mutant in hypoxia lead to the accumulation of equivalent levels of succinate in the media, as is observed with wild type control. These observations point towards redundancy in the FRD and SDH function in Mtb. In line with these, sdh2 of M. smegmatis is upregulated during hypoxia while sdh1 is induced during energy limiting conditions (Berney and Cook, 2010). These observations again suggest a functional redundancy ( ). However, analysis of Mtb SDH1 and SDH 2 suggested a subtle difference in the two. It was observed that the deletion of SDH1 results in an alteration in the rate of respiration associated with the inability to recover from the stationary phase (Hartman et al., 2014). Nonetheless, such a functional redundancy is a major roadblock in targeting FRD/SDH of Mtb and suggests that inhibitors capable of inhibiting all three enzymes despite genetics and structural differences may target FRD/SDH of Mtb (Hards et al., 2020).

Figure 7

Role of fumarate reductase/succinate dehydrogenase as an alternate respiratory pathway. Under hypoxic conditions, fumarate can act as an alternate electron acceptor. For this either fumarate reductase is utilized or succinate dehydrogenase perform the reverse reaction. Succinate is secreted out of the cells.

Synergy Between Inhibitors of Terminal Respiratory Oxidases

Emerging literature suggests that Mtb shows a high level of flexibility in utilizing both of its terminal respiratory oxidases for survival and/or growth (Arora et al., 2014; Kalia et al., 2017b; Moosa et al., 2017; Scherr et al., 2018; Beites et al., 2019). Knock out strains of Mtb lacking bc oxidoreductase (Beites et al., 2019) or cytochrome bd oxidase (Moosa et al., 2017) have been created, suggesting these oxidases could suffice each other’s function and thus are redundant. These observations raise questions over the suitability of the terminal oxidases as a drug target. Notably, mutants lacking a functional cytochrome bd oxidase are hyper susceptible to the inhibitors of bc oxidoreductase (Arora et al., 2014; Kalia et al., 2017a; Moosa et al., 2017), and mutants lacking functional bc oxidoreductase are highly susceptible to inhibitors of bd oxidase (Lu et al., 2015). These studies suggest that simultaneous inhibition of both terminal respiratory oxidases is bactericidal in vitro and in vivo (Kalia et al., 2017a; Beites et al., 2019). Importantly, such an approach is successful at killing replicating as well as non-replicating persistent bacteria. We believe that the synergistic inhibition of both the terminal oxidases represents an ideal drug development strategy ( ). It was recently demonstrated that bc oxidoreductase inhibitor Q203 and ATP synthase inhibitor leads to increased respiration in Mtb cells (Lamprecht et al., 2016). Importantly, this study also elucidated that a combination of BDQ, Q203, and clofazimine is extremely potent at killing mycobacterial cells in culture medium (Lamprecht et al., 2016). Testing animal infection with such a regiment and its comparison vis a vis isoniazid/rifampicin/pyrazinamide/ethambutol could further establish the validity of bioenergetics as one of the best drug targets available. It is important to note that BDQ lack bactericidal activity during the initial 3-4 days although its exposure leads to depletion of ATP within 3 h (Koul et al., 2014). It could be hypothesized that Mtb may survive during first few days in the presence of BDQ through limited substrate-level phosphorylation. Glycolysis is a major catabolic pathway that leads to production of ATP in Mtb cells. In the light of these, we propose that the inclusion of a glycolysis inhibitor such as 2-deoxyglucose (Jin et al., 2016) may synergize with the combination of BDQ, Q203, and clofazimine and thus could be very effective at killing mycobacterial cells in vitro and in vivo. Such a hypothesis needs to be tested to increase the efficacy of respiratory inhibitors in the mycobacterial killing. Furthermore, transposon mutagenesis based screens could be utilized for discovering pathways utilized by Mtb for generation of ATP in the presence of BDQ. Development of inhibitors of these pathways could be prioritized. Once such inhibitors are identified, they could be used in combination with BDQ and clofazimine.

Concluding Remarks

Mycobacterial ETC is highly flexible and efficiently synchronizes with the plasticity of the central metabolic system to facilitate the survival of Mtb in varied microenvironments ranging from diverse types of granulomas to sputum droplets. During the last few years, inhibitors of ETC have raced ahead in the clinical trials, and few are even approved for the treatment of MDR-TB and XDR-TB. Amongst the components of ETC, terminal oxidases stand out as a druggable target. Several classes of chemical compounds capable of inhibiting cytochrome bc oxidase are known, including Imidazopyridine amides, Arylvinylpiperazine amide, Morpholinothiophene, Pyrrolopyridinedione, Quinazolinamines, Quinolinones, Benzimidazoles, Pyrazolopyridine amides, Imidazothiazole amide, Imidazopyridine ethers, 2-(Quinolin-4-yloxy)acetamides. However, only a few classes of chemical compounds capable of inhibiting the cytochrome bd oxidase are known, including quinone analogs of the Aurachin family, a quinolone derivative CK-2-63, and a novel cytochrome bd oxidase specific inhibitor, MQL-H2, of imidazole class. Evidence emerging from hyper-susceptibility of one terminal oxidase mutant to the inhibitors of other terminal oxidase opens up the door for developing a new regimen where a combination of inhibitors targeting both the terminal oxidases can be used for the treatment of TB. In this direction, identifying novel cytochrome bd oxidase inhibitors should be a priority. Combination therapy could help in the shortening of the treatment duration. A regimen targeting several different pathways such as oxidative phosphorylation, cell wall biosynthesis, and RNA/protein biogenesis could emerge as a universal regimen capable of treating drug-susceptible, MDR-TB, and XDR-TB patients. TB community, along with the pharma companies, have embarked upon this mission, which has led to the strengthening of the TB drug pipeline. We are optimistic that this will lead to the evolution of new regimens for TB treatment in the future.

Author Contributions

SB and AK conceptualized the structure of the manuscript. SB, NB, MK, GP, VC, and AK wrote the manuscript. NB and SB also helped with the illustrations of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work is supported by Swarnajayanti Fellowship (DST/SJF/LSA-02/2016-17) and National Bioscience Award (BT/HRD-NBA-NWB/37/01/2018) from DST and DBT, Govt of India, respectively.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.